BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aghel N, Delgado DH, Lipton JH. Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines? Leukemia 2018;32:2095-104. [PMID: 30201984 DOI: 10.1038/s41375-018-0247-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Lipton JH, Brümmendorf TH, Gambacorti-passerini C, Garcia-gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100968] [Reference Citation Analysis]
2 Mauro MJ. Lifelong TKI therapy: how to manage cardiovascular and other risks. Hematology Am Soc Hematol Educ Program 2021;2021:113-21. [PMID: 34889360 DOI: 10.1182/hematology.2021000239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Baggio D, Tan S, Porch K, Shortt J, Ko B. Prediction of cardiovascular events in patients with chronic myeloid leukaemia using baseline risk factors and coronary artery calcium scoring. Intern Med J 2021;51:1736-40. [PMID: 34664363 DOI: 10.1111/imj.15517] [Reference Citation Analysis]
4 Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 2019;3:851-61. [PMID: 30885996 DOI: 10.1182/bloodadvances.2018025874] [Cited by in Crossref: 32] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
5 Saussele S, Haverkamp W, Lang F, Koschmieder S, Kiani A, Jentsch-Ullrich K, Stegelmann F, Pfeifer H, La Rosée P, Goekbuget N, Rieger C, Waller CF, Franke GN, le Coutre P, Kirchmair R, Junghanss C. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol 2020;143:217-31. [PMID: 31590170 DOI: 10.1159/000501927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]